GMZ 2 vaccine(Statens Serum Institute)(GMZ 2 vaccine(Statens Serum Institute))

概要

基本信息

药物类型

预防性疫苗

别名

GMZ 2 [GLURP+MSP3]、GMZ2

靶点

MSP3 x PfGARP

作用机制

MSP3抑制剂(裂殖子表面蛋白 3 抑制剂)、PfGARP抑制剂(恶性疟原虫GARP蛋白抑制剂)、免疫刺激剂

治疗领域

感染

在研适应症-

非在研适应症

恶性疟

原研机构

Statens Serum Institute

在研机构-

非在研机构

European & Developing Countries Clinical Trials Partnership

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 GMZ 2 vaccine(Statens Serum Institute) 相关的临床试验

NCT00703066 / Unknown status临床1期IIT

A Phase I, Randomized, Controlled, Double-Blind, Single Centre Trial to Evaluate the Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years

The study aims to show that the candidate malaria vaccine GMZ2 is as safe as the already publicly used vaccine against rabies. 30 Gabonese children aged 1-5 years will be enrolled and randomly allocated to receive either malaria vaccine or rabies vaccine without the investigator or the participants knowing what they received. They will receive 3 doses each at one month intervals, and will be followed up for one year to evaluate safety parameters. 30 and 100µg doses for the candidate malaria vaccine GMZ 2 will be evaluated for safety.
This is the second time that candidate malaria vaccine GMZ 2 is being tested in Africa, the first time being in Gabonese adults where the product was found to be safe.

开始日期2008-06-01

申办/合作机构

African Malaria Network Trust

NCT00397449 / Unknown status临床1期IIT

Assessment of the Safety and Immunogenicity of the Recombinant Lactococcus Lactis Hybrid GMZ2 [GLURP+MSP3] a Malaria Vaccine in Healthy Adult Volunteers. A Phase I, Double-Blind, Randomised, Dose-Selection, Unicentre Trial

This is a randomized, open, dose-selection Phase 1 study. The study aims to evaluate the safety and immunogenicity of 3 doses (10,30 & 100 micrograms) of the GMZ2 hybrid (GLURP and MSP3) blood stage vaccine in healthy non-immune European adults. The vaccines will be administered with aluminum hydroxide as adjuvant. The safety and the tolerability of the vaccine will be assessed on the rate of solicited and unsolicited events/reactions related to the vaccine. The safety profile will include local and systemic reactions/events as well as the biological safety, based on a clinically significant change of the baseline value of the main biological criteria. The immunogenicity of the different formulation of the vaccine will be assessed on the level and the quality of circulating antibodies as well as the stimulation of the T-cell immune response.

开始日期2006-10-01

申办/合作机构

European Vaccine Initiative

100 项与 GMZ 2 vaccine(Statens Serum Institute) 相关的临床结果

登录后查看更多信息

100 项与 GMZ 2 vaccine(Statens Serum Institute) 相关的转化医学

登录后查看更多信息

100 项与 GMZ 2 vaccine(Statens Serum Institute) 相关的专利（医药）

登录后查看更多信息

14

项与 GMZ 2 vaccine(Statens Serum Institute) 相关的文献（医药）

2022-11-01·Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

Article

作者: Mesas, Cristina ; Perazzoli, Gloria ; Muñoz-Gámez, Jose A ; Melguizo, Consolación ; Quiñonero, Francisco ; Ortiz, Raul ; Prados, Jose ; Jiménez-Luna, Cristina

Pancreatic cancer (PC) is one of the tumors with the lowest survival rates due to the poor efficacy of the treatments currently used. Gemcitabine (GMZ), one of the chemotherapeutic agents employed when the tumor is unresectable, frequently fails due to the development of drug resistance. PARP1 is a relevant protein in this phenomenon and appears to be related to cancer progression in several types of tumors, including PC. To determine the relevance of PARP1 in the development and treatment of PC, we used the Panc02 cell line to generate modified PC cells with stably inhibited PARP1 expression (Panc02-L) and used GMZ, Olaparib (OLA) and GMZ+OLA as therapeutic strategies. Viability, radiosensitization, angiogenesis, migration, colony formation, TUNEL, cell cycle, multicellular tumorsphere induction and in vivo assays were performed to test the influence of PARP1 inhibition on resistance phenomena and tumor progression. We demonstrated that stable inhibition or pharmacological blockade of PARP1 using OLA-sensitized Panc02 cells against GMZ significantly decreased their IC₅₀, reducing colony formation capacity, cell migration and vessel formation (angiogenesis) in vitro. Furthermore, in vivo analyses revealed that Panc02-L-derived (PARP1-inhibited) tumors showed less growth and lethality, and that GMZ+OLA treatment significantly reduced tumor growth. In conclusion, PARP1 inhibition, both alone and in combination with GMZ, enhances the effectiveness of this chemotherapeutic agent and represents a promising strategy for the treatment of PC.

2021-08-01·Environmental science and pollution research international3区 · 环境科学与生态学

Fractal approach in expansive clay-based materials with special focus on compacted GMZ bentonite in nuclear waste disposal: a systematic review

3区 · 环境科学与生态学

Review

作者: Li, Xiaoyue ; Iqbal, Mudassir ; Jamhiri, Babak ; Xu, Yongfu ; Jalal, Fazal E

Knowledge of the behavior of highly compacted expansive clays, as an engineered barrier, in disposal of high-level nuclear waste (HLW) systems to prevent the pollution due to migration of radionuclide is extremely essential. The prominent properties of globally and widely used bentonites have been extensively studied during past two decades. In China, GaoMiaoZi (GMZ) bentonite is the first choice as a buffer or backfill material for deep geological repositories. This review article presents the recent progresses of knowledge on water retention properties, hydromechanical behavior, and fractal characteristics of GMZ bentonite-based materials, by reviewing 217 internationally published research articles. Firstly, the current literature regarding hydrogeochemical and mechanical characteristics of GMZ bentonite influenced by various saline solutions are critically summarized and reviewed. Then, the role of osmotic suction π alongside the application of surface fractal dimension D_s is presented from the standpoint of fractal theory. Finally, the strength characteristics of GMZ bentonites using fractal approach have been discussed. Furthermore, this study sheds light on gaps, opportunities, and further research for understanding and analyzing the long-term hydromechanical characteristics of the designed backfill material, from the standpoint of surface fractality of bentonites, and implications of sustainable buffer materials in the field of geoenvironmental engineering.

2020-07-01·Environmental science and pollution research international3区 · 环境科学与生态学

The sorption performance of corroded Gaomiaozi bentonite by evolved cement water at different temperatures: the case of europium removal

3区 · 环境科学与生态学

Article

作者: Ye, Wei-Min ; Chen, Yong-Gui ; Shang, Yinghui ; Wu, Dong-Bei ; Sun, Zhao ; Cui, Yu-Jun

In the Chinese high-level radioactive waste geological disposal program, Gaomiaozi (GMZ) bentonite has been selected as the potential buffer/backfill material. After the closure of the repository, the Ca-OH-type alkaline solution (evolved cement water) released by cement degradation may last for more than 100,000 years. The bentonite will undergo the corrosion of evolved cement water (ECW) for a long period. This work focuses on the sorption property of GMZ bentonite altered by ECW. Firstly, the corrosion experiments on compacted GMZ specimens with the dry density of 1.70 Mg/m³ were carried out under constant volume conditions at two temperatures. Then, the sorption of europium (Eu (III)) onto the corroded GMZ bentonite was studied by batch experiments. The results of batch sorption tests indicate that the altered GMZ bentonite keeps an effective removal property with the uptake of Eu (III) more than 99%. The effect of high-temperature conditions of the repository on the sorption property of bentonite is not significant. The results also suggest that the evolved cement water presents no detrimental effect on the long-term adsorption performance of bentonite even under higher temperature conditions.

100 项与 GMZ 2 vaccine(Statens Serum Institute) 相关的药物交易

登录后查看更多信息